Figure 4.

The mixed cannabinoid CB1/CB2 agonist WIN55,212-2 (0.5 mg/kg/day s.c.) and the CB2-preferring agonist, AM1710 (3.2 mg/kg/day s.c.) suppressed the development of both a. mechanical and b. cold allodynia associated with paclitaxel treatment. No antinociception was observed in cremophor animals treated with either cannabinoid agonist in response to mechanical or cold stimulation.*P <0.05, **P <0.01,***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P <0.01, ###P <0.001 All conditions vs. Taxol-Vehicle (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27
Download authors' original image